Compass Therapeutics

71 articles about Compass Therapeutics

• Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

  4/16/2024

  Compass Therapeutics, Inc. today announced that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a PD-1 x PD-L1 bispecific antibody, in patients with solid tumors.

• Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

  4/12/2024

  Compass Therapeutics, Inc. today announced poster presentations on CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024.

• Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

  4/10/2024

  Compass Therapeutics, Inc. announced that the Company will participate in the Stifel Targeted Oncology Days taking place virtually April 16 – 17, 2024.

• Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

  4/9/2024

  Compass Therapeutics, Inc. (Nasdaq: CMPX) today presents a poster on the combination of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471, on anti-tumor activity in preclinical models at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, California on April 9.

• Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

  3/21/2024

  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported full 2023 financial results and provided business update.

• Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

  2/29/2024

  Compass Therapeutics, Inc. announced that the Company will participate in the Leerink Partners Global Biopharma Conference in Miami Beach, Florida on Wednesday, March 13, 2024.

• Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

  2/28/2024

  Compass Therapeutics, Inc. (Nasdaq: CMPX) announced the publication of a peer-reviewed article titled, “A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity” in the journal OncoImmunology.

• Compass Therapeutics Provides Corporate Update - Jan 05, 2024

  1/5/2024

  Compass Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported a business update.

• Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/9/2023

  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date, 2023 financial results.

• Compass Therapeutics to Participate in Upcoming November 2023 Investor Events

  11/7/2023

  Compass Therapeutics, Inc. announced that the Company will participate in the following investor events during the month of November 2023.

• Compass Therapeutics to Participate in Upcoming September 2023 Investor Events

  8/30/2023

  Compass Therapeutics, Inc. announced that the Company will participate in the following investor events during the month of September 2023.

• Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/3/2023

  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported second quarter, and year-to-date, 2023 financial results.

• Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

  6/22/2023

  Compass Therapeutics, Inc. announced that it will be added to the Russell 2000® and Russell 3000® Indexes as part of the Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023.

• Compass Therapeutics to Participate in Upcoming June 2023 Investor Events

  6/1/2023

  Compass Therapeutics, Inc. announced that the Company will participate in the following investor events during the month of June 2023.

• Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

  5/4/2023

  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2023 financial results.

• Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

  4/26/2023

  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the H.C. Wainwright BioConnect Investor Conference in New York City on Tuesday, May 2, 2023.

• Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

  4/19/2023

  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2023 Virtual Targeted Oncology Days, which is taking place on April 25 – 26, 2023.

• Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

  3/28/2023

  Compass Therapeutics, Inc. (Nasdaq: CMPX) today announced that the Company will participate in the Cantor Fitzgerald Future of Oncology Symposium, which is taking place virtually on April 3 – 5, 2023.

• Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/15/2023

  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported fourth quarter and full year 2022 financial results.

• Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

  2/2/2023

  Compass Therapeutics, Inc. today announced that the Company will participate in the SVB Securities Global Biopharma Conference, which is taking place virtually on February 13 – 16, 2023.